Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2009;8(4):383-90.
doi: 10.1007/s10689-009-9251-y. Epub 2009 May 26.

TP53 germline mutations in Portugal and genetic modifiers of age at cancer onset

Affiliations

TP53 germline mutations in Portugal and genetic modifiers of age at cancer onset

Carla Pinto et al. Fam Cancer. 2009.

Abstract

The Li-Fraumeni syndrome (LFS) is a rare, autosomal dominant disease caused by TP53 germline mutations. This study aimed to characterize the TP53 mutational spectrum in patients suspected to have LFS in Portugal and to evaluate the influence of the MDM2-SNP309 and TP53-72Arg variants and of telomere length on age of tumor onset. Probands were primarily selected using the classical LFS criteria (two cases) or the more sensitive Chompret Li-Fraumeni-like (LFL) criteria (13 cases), but 12 additional patients that did not comply with those LFS or LFL criteria were included in the analysis based on clinical suspicion (LFS suspects). Nine of the 27 probands (33.3%) presented germline TP53 mutations, two of them occurring de novo and two of them being novel. Three of the nine TP53 mutations were found in families that did not comply with any of the commonly used criteria for TP53 testing, leaving room to recommend the use of less stringent criteria. An association was found between the presence of the TP53-72Arg (but not the MDM2-SNP309) variant and earlier age of onset in TP53 carriers. A negative correlation between telomere length and age of cancer onset was found in patients with germline TP53 mutation, whereas no such correlation was found in controls or in patients with wild-type TP53.

PubMed Disclaimer

References

    1. Science. 1990 Nov 30;250(4985):1233-8 - PubMed
    1. Br J Cancer. 1994 Dec;70(6):1176-81 - PubMed
    1. Cancer Surv. 1995;25:101-24 - PubMed
    1. Cell. 2004 Nov 24;119(5):591-602 - PubMed
    1. J Med Genet. 2004 Jun;41(6):e89 - PubMed

Publication types

Substances